Lineage Cell Therapeutics, Inc. (LCTX)
NYSEAMERICAN: LCTX · Real-Time Price · USD
1.850
+0.010 (0.54%)
Mar 6, 2026, 4:00 PM EST - Market closed
Lineage Cell Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 14.56 | 9.5 | 8.95 | 14.7 | 4.34 | Upgrade
|
| Revenue Growth (YoY) | 53.24% | 6.19% | -39.16% | 238.70% | 137.73% | Upgrade
|
| Cost of Revenue | 0.15 | 12.81 | 16.38 | 0.73 | 1.43 | Upgrade
|
| Gross Profit | 14.41 | -3.31 | -7.43 | 13.98 | 2.92 | Upgrade
|
| Selling, General & Admin | 18.46 | 18.17 | 13.77 | 22.51 | 18.21 | Upgrade
|
| Research & Development | 17.73 | - | - | 13.99 | 33.91 | Upgrade
|
| Operating Expenses | 36.19 | 18.17 | 13.77 | 36.5 | 52.13 | Upgrade
|
| Operating Income | -21.78 | -21.48 | -21.2 | -22.52 | -49.21 | Upgrade
|
| Interest & Investment Income | 1.69 | 1.72 | 1.63 | 0.83 | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | 2.15 | -0.57 | -1.04 | -2 | 1.49 | Upgrade
|
| Other Non Operating Income (Expenses) | -35.86 | 1.76 | 0.54 | 0.07 | 0.21 | Upgrade
|
| EBT Excluding Unusual Items | -53.8 | -18.57 | -20.08 | -23.62 | -47.52 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.01 | -0.01 | -0.18 | -2.19 | 3.73 | Upgrade
|
| Asset Writedown | -14.84 | - | - | - | - | Upgrade
|
| Legal Settlements | - | - | -3.53 | - | - | Upgrade
|
| Other Unusual Items | - | - | 0.5 | - | 0.52 | Upgrade
|
| Pretax Income | -68.65 | -18.58 | -23.28 | -25.81 | -43.27 | Upgrade
|
| Income Tax Expense | -5.28 | - | -1.8 | 0.54 | - | Upgrade
|
| Earnings From Continuing Operations | -63.37 | -18.58 | -21.48 | -26.35 | -43.27 | Upgrade
|
| Minority Interest in Earnings | -0.17 | -0.03 | -0.01 | 0.08 | 0.25 | Upgrade
|
| Net Income | -63.53 | -18.61 | -21.49 | -26.27 | -43.02 | Upgrade
|
| Net Income to Common | -63.53 | -18.61 | -21.49 | -26.27 | -43.02 | Upgrade
|
| Shares Outstanding (Basic) | 230 | 200 | 173 | 170 | 165 | Upgrade
|
| Shares Outstanding (Diluted) | 230 | 200 | 173 | 170 | 165 | Upgrade
|
| Shares Change (YoY) | 14.95% | 15.94% | 1.69% | 3.22% | 9.64% | Upgrade
|
| EPS (Basic) | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 | Upgrade
|
| EPS (Diluted) | -0.28 | -0.09 | -0.12 | -0.15 | -0.26 | Upgrade
|
| Free Cash Flow | -19.44 | -23.66 | -29.24 | 0.65 | -23.9 | Upgrade
|
| Free Cash Flow Per Share | -0.08 | -0.12 | -0.17 | 0.00 | -0.14 | Upgrade
|
| Gross Margin | 99.00% | -34.81% | -83.07% | 95.05% | 67.15% | Upgrade
|
| Operating Margin | -149.62% | -226.11% | -237.04% | -153.17% | -1133.63% | Upgrade
|
| Profit Margin | -436.47% | -195.91% | -240.20% | -178.69% | -990.99% | Upgrade
|
| Free Cash Flow Margin | -133.56% | -249.05% | -326.89% | 4.39% | -550.59% | Upgrade
|
| EBITDA | -21.08 | -20.87 | -20.51 | -21.79 | -48.34 | Upgrade
|
| EBITDA Margin | -144.82% | -219.70% | -229.30% | -148.22% | - | Upgrade
|
| D&A For EBITDA | 0.7 | 0.61 | 0.69 | 0.73 | 0.87 | Upgrade
|
| EBIT | -21.78 | -21.48 | -21.2 | -22.52 | -49.21 | Upgrade
|
| EBIT Margin | -149.62% | -226.11% | -237.04% | -153.17% | - | Upgrade
|
| Revenue as Reported | 14.56 | 9.5 | 8.95 | 14.7 | 4.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.